Celldex Therapeutics (CLDX) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Celldex Therapeutics (CLDX) over the last 16 years, with Q2 2025 value amounting to 8747.53%.
- Celldex Therapeutics' EBIT Margin fell 68933700.0% to 8747.53% in Q2 2025 from the same period last year, while for Sep 2025 it was 9855.38%, marking a year-over-year decrease of 79841100.0%. This contributed to the annual value of 2778.89% for FY2024, which is 5336200.0% down from last year.
- Per Celldex Therapeutics' latest filing, its EBIT Margin stood at 8747.53% for Q2 2025, which was down 68933700.0% from 9027.19% recorded in Q1 2025.
- Celldex Therapeutics' EBIT Margin's 5-year high stood at 386.21% during Q2 2021, with a 5-year trough of 26030.77% in Q1 2024.
- Moreover, its 5-year median value for EBIT Margin was 5429.04% (2021), whereas its average is 7690.27%.
- In the last 5 years, Celldex Therapeutics' EBIT Margin tumbled by -226728600bps in 2024 and then skyrocketed by 170035700bps in 2025.
- Over the past 5 years, Celldex Therapeutics' EBIT Margin (Quarter) stood at 6089.82% in 2021, then surged by 72bps to 1728.77% in 2022, then skyrocketed by 33bps to 1152.92% in 2023, then plummeted by -314bps to 4768.26% in 2024, then plummeted by -83bps to 8747.53% in 2025.
- Its EBIT Margin was 8747.53% in Q2 2025, compared to 9027.19% in Q1 2025 and 4768.26% in Q4 2024.